17 results about "Cd4 t cell" patented technology

The technology described herein is directed to methods of generating CD4+CD8- single-positive T cells from CD4+CD8+ double positive T progenitor cells using differentiation in the presence of interleukin-7 (IL-7) and an anti-CD3 agent and in absence of Notch ligand and an anti-CD28 agent. Also described herein are CD4+CD8- single-positive T cells made by the methods described herein, which can be used for therapeutic applications.

The present invention relates to a T cell receptor (TCR) that specifically binds to a KRAS_G12V mutant antigen, a fusion protein or complex containing a TCR, a nucleic acid encoding a TCR, genetically modified cells containing the same, and a method for producing genetically modified cells. The present invention also relates to enhancing T cell function by coexpressing an exogenous CD8 molecule and a TCR gene in T cells. The present invention provides uses of the TCR and genetically modified cells in the detection, prevention, and / or treatment of cancers associated with the KRAS_G12V mutant antigen.

A vaccine for use in the prophylaxis and / or treatment of a diseaseThe present invention relates to an adenoviral vector capable of encoding a virus-like particle (VLP), said VLP displaying an inactive immune-suppressive domain (ISD). The vaccine of the invention shows an improved immune response from either of both of the response pathways initiated by CD4 T cells or CD8 T cells.

A method for determining whether a subject is at risk for having a progressing or high-grade pre-invasive lesion, nodule or small mass, or having a solid malignant tumour is described the method comprising: (i) determining a ratio of activated and / or exhausted T cells:naive and / or resting T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, or (ii) determining a ratio of activated and / or exhausted T cells:T cells which are not activated and / or exhausted T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence or absence of a panel of biomarkers comprising Ki67 and CD39, (iii) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising Ki67 and CD39, and / or (iv) determining a proportion of activated and / or exhausted T cells as a percentage of T cells in a sample of blood obtained from the subject, wherein the T cells are CD4 T cells, and wherein the determining comprises analysing T cells using cytometry to detect the presence of a panel of biomarkers comprising FoxP3.

The application discloses a material for improving tumor microenvironment and a preparation method and application thereof, and relates to a material comprising: a magnesium-containing metal, and nano calcium carbonate particles for modifying the surface of the magnesium-containing metal; wherein the mass ratio of the magnesium-containing metal and the nano calcium carbonate particles is 10:1-4:1. + The application finds that the magnesium metal can inhibit CAFs from releasing cancer-promoting factors and weaken the inhibition of immune cells by CAFs by releasing hydrogen, thereby enhancing the expression of activation genes in CD4 T cells, and achieving the effect of improving the tumor microenvironment. Based on this, the application develops a material for improving the tumor microenvironment. The degradation rate of the magnesium metal material is moderate, and the material can weaken the inhibition of immune cells by CAFs, achieve the effect of improving the tumor microenvironment, and improve the tumor treatment effect of immunotherapy.

The technology described herein is directed to methods of generating CD4+CD8− single-positive T cells from CD4+CD8+ double positive T progenitor cells using differentiation in the presence of interleukin-7 (IL-7) and an anti-CD3 agent and in absence of Notch ligand and an anti-CD28 agent. Also described herein are CD4+CD8− single-positive T cells made by the methods described herein, which can be used for therapeutic applications.

This invention discloses the role of the POFUT1 gene in determining the function of tissue-infiltrating CD4+ T cells and the application of related biomarkers in diseases, belonging to the field of biomedical technology. This invention discovers that POFUT1 is a decisive gene regulating the development of CXCR5+CD4 T cells; simultaneously, CXCR5+ and SLAMF1+CD4 T cells, as tissue-infiltrating source cells, possess the function of carrying out CD4 T cell-mediated antigen-specific killing and tissue destruction, leading to the pathogenesis of autoimmune diseases. Related applications include: using the POFUT1 gene, CXCR5+, and SLAMF1+CD4 T cells as biomarkers for the clinical diagnosis and treatment of diseases caused by tissue-infiltrating CD4 T cells, such as autoimmune diseases and xenotransplant rejection. The killing function of CXCR5+ and SLAMF1+CD4 T cells as tissue-infiltrating source cells can also be used to treat tumors.

Compositions of chimeric antigen receptor (CAR) constructs, CAR-T cell compositions of T cells modified to express CAR constructs, and methods of use thereof for the treatment of neurodegenerative diseases are provided. Exemplary CAR construct embodiments include: an antigen-binding domain, wherein the antigen-binding domain targets a neurodegenerative-associated protein; a co-stimulatory domain; and a Cd3e signaling domain. Exemplary methods of inducing T cell activation include modifying a CD4 T cell to express a CAR construct as disclosed herein and exposing the modified CD4 T cell to the neurodegenerative-associated protein to induce CD4 T cell activation. Exemplary methods of treating a neurodegenerative disease in a subject in need thereof include administering to the subject a modified CAR-T cell composition containing CD4 T cells modified to express a chimeric antigen receptor (CAR) construct as disclosed herein.

This invention relates to adenovirus vectors capable of encoding virus-like particles (VLPs) exhibiting an inactive immunosuppressive domain (ISD). The vaccines of this invention demonstrate improved immune responses originating from either CD4 T cell or CD8 T cell-initiated pathways.

The invention discloses siRNA (small interfering Ribonucleic Acid) for inhibiting HIV-1 (Human Immunodeficiency Virus-1) replication and transcription reactivation by targeting PRMT3 (Porcine Reproductive and Protein Transfer 3). According to the application, a plurality of siRNAs capable of targeting PRMT3 are designed, the effect of the siRNAs for knocking down the PRMT3 in MT4 cells is evaluated, and the siRNAs capable of knocking down the PRMT3 in the MT4 cells are screened out; the method comprises the following steps: screening out siRNA (small interfering Ribonucleic Acid), then respectively using MT4 cells infected with HIV-1 virus and primary CD4 + T cells of an HIV infected patient to evaluate and verify the influence of the screened siRNA to knock down PRMT3 on HIV-1 virus replication and latent reactivation, finally discovering that the knock down PRMT3 can inhibit siRNA-2 of HIV-1 virus replication and latent reactivation, perfecting an evidence chain for treating HIV-1 by targeting PRMT3, and providing a new possibility for treatment of HIV-1 infection.

The invention provides a method for treating hepatocellular carcinoma (HCC) by utilizing cytokines to recruit eosinophilic granulocytes. According to the invention, single sample gene set enrichment analysis (ssGSEA) is adopted to calculate a hepatocellular carcinoma immune infiltration score, and eosinophilic granulocyte infiltration is screened out, so that the lifetime of an HCC patient can be prolonged. Experiments prove that by collecting eosinophilic granulocytes through cytokines, activation and proliferation of NK cells, CD8 T cells and CD4 T cells in the liver can be directly or indirectly promoted, and secretion of IFN-gamma can be promoted, so that liver cancer cells are killed. Therefore, the invention provides application guidance for accurate and effective treatment of HCC.

The application discloses application of a UFMylation regulator in preparation of a medicine for resisting HIV infection. + The application evaluates the inhibiting effect of the UFMylation regulator, namely, the UFSP2 inhibitor Compound-8, on HIV virus through in-vivo and in-vitro pharmacodynamic experiments. The experimental results show that Compound-8 can significantly inhibit the replication of HIV virus in MT-4 cells, primary CD4 T cells and mice, can maintain a low viral load after drug withdrawal, and has no obvious influence on the proliferation of normal cells and the weight of mice, and has good anti-HIV infection effect and high safety. The application firstly discloses that Compound-8 effectively inhibits HIV-1 replication, indicates that Compound-8 can be used as a candidate medicine for HIV-1 treatment medicine, provides a new treatment strategy for AIDS, and has a wide application prospect in the field of anti-HIV infection.

The present invention relates to a T cell receptor (TCR) specifically binding to KRAS_G12V mutant antigen, a fusion protein or a conjugate comprising the TCR, a nucleic acid encoding the TCR, and an engineered cell comprising the same, and a method for preparing the engineered cell. The present invention further relates to co-expressing an exogenous CD8 molecule and the TCR gene in T cells to enhance the function of T cells. The present invention provides use of the TCR and the genetically engineered cell in the detection, prevention and / or treatment of cancers related to the KRAS_G12V mutant antigen.

The present invention relates to viral vectors co-encoding an artificial CD4 T cell epitope (PADRE) for enhanced immune responses to encoded multimeric protein particle displayed vaccine antigens.

The application discloses an isolated antibody and application thereof.The isolated antibody comprises a heavy chain variable region and a light chain variable region, and comprises one or more of the following technical features: the heavy chain variable region comprises CDR-H1 with an amino acid sequence as shown in SEQ ID No.1; the heavy chain variable region comprises CDR-H2 with an amino acid sequence as shown in SEQ ID No.2; the heavy chain variable region comprises CDR-H3 with an amino acid sequence as shown in SEQ ID No.3; the light chain variable region comprises CDR-L1 with an amino acid sequence as shown in SEQ ID No.4; the light chain variable region comprises CDR-L2 with an amino acid sequence of VAS; and the light chain variable region comprises CDR-L3 with an amino acid sequence as shown in SEQ ID No.5.The isolated antibody of the application can efficiently target CD4 antigens, efficiently enrich CD4 T cells, and the CAR-T cells prepared from the enriched CD4 T cells can be activated by antigens.

The application discloses siPRMT3 in HIV infection, and designs a plurality of siRNAs which can target PRMT3, evaluates the effect of the siRNAs on knocking down PRMT3 in MT4 cells, and screens out siRNAs which can knock down PRMT3 in MT4 cells. + MT4 cells infected with HIV-1 virus and primary CD4 T cells of HIV infected patients are used respectively, the influence of the screened siRNAs on HIV-1 virus replication and latent reactivation is evaluated and verified, finally, siRNAs which can inhibit HIV-1 virus replication and latent reactivation by knocking down PRMT3 are found, the evidence chain of treating HIV-1 by targeting PRMT3 is perfected, and a new possibility is provided for the treatment of HIV-1 infection.

The invention discloses a preparation method of a biological agent for enhancing immune response of an infant hepatitis B vaccine generated by an HBsAg positive mother based on a dendritic cell exosome. The preparation method comprises the following steps: obtaining the dendritic cell exosome; preparing a Dex + HepB biological preparation; establishing an HBV intrauterine exposure animal model; and the Dex + HepB biological agent is used for intervening in HBV intrauterine exposed animals. In application verification, an HBV intrauterine exposure mouse model is constructed to simulate the immune state of an infant born by an HBsAg positive mother. And then, according to an immune procedure of 0-2-4 weeks, injecting the prepared Dex + HepB biological agent into the body of a model mouse. Experimental results show that the preparation can effectively improve the proportion of CD4T cells in the spleen of a mouse, improve the expression level of Th2 type cytokines and remarkably enhance the generation of anti-HBs, so that the immune response of the mouse to hepatitis B vaccines is comprehensively improved.